We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Malignant neoplasms of digestive organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Predicting the clinical course of the disease is of paramount importance in the management of hepatocellular (and other) cancers. It is felt that by investigating the molecular signature of cancer clinicians may prescribe treatments which are more likely to show benefit. This concept is particularly important for liver cancer, where Sorafenib, a multikinase inhibitor, is the only drug currently licensed for advanced hepatocellular carcinoma. Exploring the mechanisms of resistance to this drug is important i) because it provides information on design of agents to over come resistance ii) it may facilitate development of biomarkers which predict whether individual cancers are, or are likely to become, resistant to sorafenib. In the proposed study, we shall investigate genes which may give information on the patient's prognosis and, in a subset of advanced HCC patients, in mediating resistance to sorafenib. These genes will be analysed in the tumor tissue and in peripheral blood both at the DNA level (cancer cell DNA can be detected circulating in the peripheral blood of patients) and as proteins.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Type: Imaging;Physical;Active Monitoring;
You can take part if:
You may not be able to take part if:
1. Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by Imperial College of Science, Technology and Medicine and funded by NIHR Academy .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 34122
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
